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Introduction
Drug therapy for osteoporosis is widely accepted. Bis-
phosphonates in particular significantly inhibit bone
resorption by suppressing osteoclast activity and increasing
bone density [1–3]. Alendronate is one of these bisphos-
phonates; it was approved in the United States in the 1990s
and is commonly prescribed worldwide [1, 4, 5]. Clinical
trials have shown its effectiveness in the treatment of
fractures related to postmenopausal osteoporosis [6].
However, some recent reports have described unusual
subtrochanteric or femoral shaft fractures following long-
term alendronate therapy [4, 7–13]. Although no causal
relationship between long-term alendronate treatment and
these atypical stress fractures has been established, some
reports suggest that the severe suppression of bone turnover
by alendronate may lead to accumulated microdamage to
the bone that subsequently results in complete fracture
[4, 12].
In this report, we describe a patient who experienced
prodromal pain and 14 months later sustained an atrau-
matic subtrochanteric fracture after 3 years of alendronate
therapy. We include a detailed histological analysis of bone
from the unusual fracture site.
Informed consent for this report was obtained from the
patient, and the research protocol was approved by the
hospital investigational review board.
Case report
A 62-year-old woman (154 cm, 49 kg, BMI 20.7 kg/m2)
had been hospitalized for the treatment of asthma attacks.
Her medical history showed Churg-Strauss syndrome,
sinusitis, goiter, diabetes mellitus, and cerebral infarction.
She was given an oral glucocorticoid (7 mg/day) for
asthma. Oral alendronate (5 mg/day) was prescribed to
prevent glucocorticoid-induced osteoporosis; 6 months
later this was converted to one weekly tablet (35 mg/
week).
About 26 months after initiation of the therapy, the
patient experienced prodromal pain in her left thigh with-
out any trauma and consulted the orthopaedics department
as an outpatient. A radiograph at that time showed diffuse
cortical thickening on the bilateral femora and an external
cortical bone reaction on the left femur, but no fracture
(Fig. 1a). MR imaging showed cortical thickening and
atypical signaling on both the endosteum and periosteum
surfaces in the same region of the left femur (Fig. 1b). We
recommended partial weight bearing and restricted activi-
ties, and the pain soon decreased. Bone mineral density
(BMD) of the L2–L4 vertebrae measured by dual-energy
X-ray absorptiometry (DEXA) 1 month before the fracture
was a T-score of -0.5, which is not in the osteoporotic
range defined by the World Health Organization [14].
Laboratory investigations made 3 months before the injury
and biochemical markers of bone turnover taken just after
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the fracture are summarized in Table 1. These results were
all within reference ranges.
Fourteen months after prodromal pain, she experienced
acute pain on her left thigh while walking and turning
around in the hospital ward, and then fell down. Radiog-
raphy showed a subtrochanteric fracture of the left femur
classified as AO type 31-A3 accompanied by diffuse cor-
tical thickening, external cortical bone reaction, and a
cortical spike (Fig. 2). The fracture occurred in the same
region where atypical findings had been observed in the
radiograph and MR images at her first visit.
Operation and histological examination
Surgery was performed 8 days after the injury. Alendro-
nate treatment was discontinued before the operation. The
fracture was treated with internal fixation using a plate
(NCB distal femur, Zimmer Trauma, Warsaw, IN) on the
tension side of the femur because the medullary canal had
been distinctly narrowed by the diffuse cortical thickening,
making it impossible to insert any intramedullary nailing.
We did not perform bone grafting to the fracture site
because bony contact was completely achieved between
fragments. A bone biopsy of the unusual hypertrophied
external ‘‘beak-shaped’’ cortex was performed intraopera-
tively for histological analysis. The fractured cortex was
extremely hard and sclerotic, like osteopetrosis (Fig. 3). A
histological examination stained by hematoxylin and eosin
showed immature new bone formation added on the
existing cortex, which included some chondroid tissues;
this was presumed to be a response to the past microfrac-
ture (Fig. 4a, b). Tertrate-resistant acid phosphatase
(TRAP) staining showed almost no TRAP-positive multi-
nucleated osteoclasts in either the existing cortex or the
newly formed bone (Fig. 4c).
Fig. 1 a Plain radiograph taken
at the first presentation of thigh
pain (14 months before the
fracture). There is a cortical
reaction (arrow) on the lateral
side of the subtrochanteric
region with diffuse cortical
thickening. b MR imaging
(coronal and axial view) shows
atypical signaling on both the
endosteum and periosteum
surfaces in the same region of
the left femur
Table 1 Laboratory investigations and biochemical markers of bone
turnover
Reference range
Serum calcium (mg/dl)a 10.0 8.0–10.5
Serum phosphate (mg/dl)a 3.5 2.5–4.5
Serum ALP (IU/l)a 161 115–359
Serum albumin (g/dl)a 4.2 4.0–5.0
TRAP-5b (mU/dl)b 188 120–420
Urine DPD/Cr (nM)b 6.4 2.8–7.6
Serum ucOC (ng/ml)b 0.46 \4.5
ALP alkaline phosphatase, TRAP-5b serum tertrate-resistant acid
phosphatase type 5b, DPD deoxypyridinoline, Cr creatinine, ucOC
undercarboxylated osteocalcin
a Data 3 months before the injury
b Data just after the fracture
Fig. 2 A plain radiograph reveals a displaced subtrochanteric
fracture of the left femur with diffuse cortical thickening and a
unilateral cortical spike
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Partial weight bearing was begun 4 weeks after the
operation and full weight bearing started after 7 weeks. At
an 8-month follow-up, the patient reported complete pain
relief. Radiographs made at that time showed abundant
callus formation on the fracture gap, and fracture healing
was achieved (Fig. 5).
We performed no preventive surgery or treatment on the
contralateral femur other than discontinuing alendronate
therapy because the patient experienced no pain on that
side and no inconvenience, although diffuse cortical
thickening was present on the radiograph [15]. No sub-
sequent pain and no additional fractures have occurred
since the follow-up.
Discussion
Bisphosphonates significantly decrease osteoclast-medi-
ated bone resorption and increase bone mineral density [2,
5, 8]. Thus, the administration of bisphosphonates is one of
the first treatments considered for the prevention of oste-
oporosis-related fractures in postmenopausal patients [3, 8,
16]. Alendronate is one of these bisphosphonates. It was
approved in the 1990s in the US and is commonly pre-
scribed worldwide [1, 5]. The effectiveness of bisphos-
phonates in the treatment of fractures related to
postmenopausal osteoporosis has been demonstrated in
numerous large clinical trials, and it has been reported that
their long-term use for up to 10 years is safe and effective
[3, 6].
However, Odvina et al. [11] first described a series of
atraumatic nonspinal fractures in patients who had been
taking alendronate for a long period, noting it as a potential
complication of alendronate therapy. Thereafter, an
increasing number of subtrochanteric or femoral shaft frac-
tures associated with long-term alendronate treatment have
been reported [4, 7–13]. Goh et al. [8] described patients who
sustained fractures in the subtrochateric region, and five of
nine patients (56%) had prodromal pain in the affected hip.
Kwek et al. [9] retrospectively reviewed 17 patients who had
sustained low-energy subtrochanteric fractures while on
alendronate therapy and reported characteristic fracture
configurations that consisted of (1) cortical thickening on the
lateral (tension) side of the subtrochanteric region, (2) a
transverse fracture, and (3) a medial cortical spike. They
reported that 9 patients (53%) had bilateral stress fractures
and 13 (76%) experienced prodromal pain before the injury.
Lenart et al. [10] also described a unique radiographic pat-
tern, defined as a simple transverse or oblique (\30) frac-
ture with beaking of the cortex and diffuse cortical
thickening of the proximal femoral shaft. Our patient shared
these same atypical radiographic patterns, with prodromal
pain prior to the injury, which corresponded to the report of a
task force of the American Society for Bone and Mineral
Research (ASBMR) [17].
Many reports have described unusual discrete thickening
(prominence) on the lateral cortex on the radiograph as well
as prodromal pain [9, 18, 19]. This external cortical reaction
in the lateral femoral tension side is thought to be caused by
microfractures at these high stress points on the skeleton [9,
13, 18, 20, 21]. The subtrochanteric region of the femur is
subject to large bending forces with compression stress on
the medial cortex and tensile stress on the external cortex [4,
7, 22]. The microdamage to the bone is repaired through
normal physiological remodeling processes by the action of
both osteoblasts and osteoclasts [17, 23]. However,
alendronate inhibits bone resorption by suppressing osteo-
clast activity and impairs bone turnover [8]. Mashiba et al.
[23] reported that in an experimental dog model bone
turnover suppression led to an accumulation of microdam-
age, resulting in reduced bone strength. The increased mi-
crodamage accumulation may increase the risk of
insufficiency fractures [8, 23]. Odvina et al. [11] reported
patients who sustained atraumatic nonspinal fractures while
Fig. 3 a Intraoperative photo of the unusual beak-shaped fracture
end (proximal side). The fractured cortex was extremely hard and
sclerotic, as in osteopetrosis. b Schema of the fracture site. The
unusual hypertrophied external ‘‘beak-shaped’’ cortex (circled by
dashed line) was excised for histological analysis. f femur, mc
medullary cavity, s skin, m muscle, r retractor
Atypical fracture on alendronate 315
123
on alendronate therapy, with histomorphometric analysis
showing severely suppressed bone turnover (SSBT). In our
case, an abnormal signal was detected by MR imaging
before the complete fracture, and the detection by bone
scintigraphy or SPECT of increased uptake at the site of the
cortical thickening has been reported by others [3, 13, 18].
Our images were consistent with a microfracture on the
lateral femoral tension side. The ellipsoid thickening was a
local response to the microfracture; our laboratory investi-
gations and bone mineral density readings were all within
the reference ranges and corresponded with those reported
previously [4, 18, 19]. Given that reiterative tensile stress is
one of the factors associated with a subtrochanteric insuf-
ficiency fracture [7], we determined that plate fixation on
the femoral tension side was a more valid procedure than
intramedullary nailing.
Some reports have advised discontinuance of alendro-
nate therapy after the identification of atypical radiographic
patterns on the proximal femur, thigh pain, or after an
Fig. 5 Internal fixation was accomplished using a plate on the
tension side of the femur without bone graft. A plain radiograph
performed at follow-up, 8 months after the operation, shows abundant
callus formation on the fracture gap; fracture healing was achieved
Fig. 4 A histological analysis of the unusual fracture end was
performed. a A lower magnification of H&E staining shows immature
new bone formation added on the existing cortex. Scale bar represents
1 mm. b A large magnification of the H&E staining of the box in
a. Upper half of the figure represents the newly formed bone, and
lower half is the existing cortex. Scale bar represents 100 lm. c On
the serial section of b, tertrate-resistant acid phosphatase (TRAP)
staining found almost no TRAP positive multinucleated osteoclasts in
either area. Methyl green was used for the counterstain
b
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insufficiency fracture has unfortunately occurred [13, 18,
24]. However, the skeletal half life of alendronate is very
long [3, 12, 25]; when discontinued, it remains in the
skeleton for years, and the physiological effect on bone
resorption has been reported to remain for up to 5 years [3,
5, 26]. Somford et al. [19] reported some patients treated
with intramedullary nailing who went into delayed union
when alendronate therapy was not discontinued. The
advantages or disadvantages of discontinuing alendronate
therapy after a fracture remain unresolved.
We also performed a bone biopsy from the unusual
lateral ‘‘beak-shaped’’ cortex, and this is one of few reports
of a biopsy from the unusual fracture end. Both hematox-
ylin/eosin and tertrate-resistant acid phosphatase (TRAP)
staining showed immature new bone formation added on
the existing cortex, which included some chondroid tissues
and almost no TRAP-positive osteoclasts in either the
existing cortex or the newly formed bone; this might be
presumed a response to the past microfracture and sup-
pressed bone remodeling.
Many patients reported to have alendronate-associated
insufficiency fractures had concurrent diseases and were
receiving many types of medications other than bisphos-
phonates. In fact, our patients had been treated for Churg-
Strauss syndrome, which was a rare diffuse vasculitis
accompanied by severe asthma and was treated with glu-
cocorticoids as first-line therapy [27]. However, there has
been no report about this syndrome per se influencing bone
metabolism. The patient also had a history of diabetes
mellitus and goiter. These conditions might influence the
occurrence of the atypical fracture; however, the influence
of these concurrent diseases and medications on the frac-
tures remains unknown [13, 19].
From the large, randomized clinical trials of bisphos-
phonates, it was concluded that there is no significant
relationship between bisphosphonate treatment and the risk
of subtrochateric or diaphyseal fracture [28, 29]. Subtro-
chanteric or diaphyseal fractures in postmenopausal
women are relatively rare, representing 2–6% of all oste-
oporotic hip fractures [5, 10]. Shane claims that the study’s
statistical power was low and, if bisphosphonate use is
causal, the benefits exceed the risk of atypical femoral
fractures [5].
In June 2010, a warning about the possibility of unusual
atraumatic subtrochanteric or femoral shaft fractures during
long-term alendronate therapy was added to the drug infor-
mation in Japan. However, atypical femoral fractures might
not be characteristics attributable only to alendronate treat-
ment. Recently, the same fracture pattern was also reported
in patients who were treated with risedronate [9, 12].
As a result of an increasing number of reports about
atypical femoral fracture (more than 300 cases), ASBMR
published the aforementioned report of a task force [17].
They defined major and minor features of atypical femoral
fracture, and our case corresponded with almost all these
features. They also described some pathogenesis that might
be associated with these atypical fractures, such as alter-
lation of collagen cross-linking, reduced heterogeneity of
mineralization and reduced vascularity in addition to the
microdamage accumulation we noted, and consequently
concluded that the precise pathogenic mechanisms were
still unknown and more information was urgently needed.
Also some case reports and animal studies have been
reported about the potential effects of parathyroid hormone
(PTH) to the suppression of bone turnover and impaired
fracture healing by bisphosphonates [30]. Further study
will be needed.
Although the causal relationship between long-term
alendronate therapy and atypical femoral fractures and its
precise mechanisms and pathogenesis are not completely
understood, awareness is needed of this potential compli-
cation. These atypical fractures could be caused by the
combination of the severe suppression of bone turnover by
long-term bisphosphponate treatment and the increased
accumulation of microdamage at the subtrochanteric
region of the femur. Clearly, additional investigations are
necessary.
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